NCT03060720Active, not recruiting
Systematic Hereditary Pancreatic Cancer Risk Assessment and Implications for Personalized Therapy
Source: ClinicalTrials.gov · Last updated 30 Mar 2026
Brief summary (registry, in English)
This research study is looking at people with cancer of the pancreas to find clinical factors that can explain the presence of genetic mutations
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 271 (actual)
- First submitted
- 15 Feb 2017
- Start date
- 24 Feb 2017
- Primary completion date
- 7 Apr 2019
- Lead sponsor
- Dana-Farber Cancer Institute
- Diseases
- Pancreatic cancer
- NCT number
- NCT03060720
What you commit to
- Study type: Observational
- Participants enrolled: 271
- From 24 Feb 2017 to the primary completion date, 7 Apr 2019
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- Prospective participant unable to sign informed consent based on referring physician recommendation.
- Patient has neuroendocrine pancreatic tumor
Who the study is looking for
- Diagnosis of pancreatic ductal adenocarcinoma
- Signed initial informed consent
- Participant agrees to genetic counseling
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Dana-Farber Cancer Institute Coordinator of this site? Confirm its status | Boston | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.